返回ChemicalBook首页>CAS数据库列表>67416-61-9

67416-61-9

中文名称 11-羰基-Β-乙酰乳香酸
英文名称 3-ACETYL-11-KETO-BETA-BOSWELLIC ACID
CAS 67416-61-9
分子式 C32H48O5
分子量 512.72
MOL 文件 67416-61-9.mol
更新日期 2024/04/26 17:06:48
67416-61-9 结构式 67416-61-9 结构式

基本信息

中文别名
绞股蓝 A
3-乙酰-11酮基乳香酸
11-羰基-Β-乙酰乳香酸
乙酰基-11酮-Β-乳香酸
11-羰基-B-乙酰乳香酸
11-羰基-Β-乙酰乳香酸
乙酰基-11-酮基-Β-乳香酸
11-羰基-Β-乙酰乳香酸标准品
11-羰基-Β-乙酰乳香酸AKBA
3-乙酰基-11-酮基-Β-乳香酸
英文别名
AKBA
AK-BETABA
AKBA, >98%
Boswellic Acid Impurity 3
BOSWELLIC ACID, ACETYL KETO
Acetyl-11-keto-b-boswellic acid
11-keto-β-boswellic acid acetate
3-Acetyl-11-keto-(-boswellicacid
3-ACETYL-11-KETO-B-BOSWELLIC ACID
3-acetyl-11-keto-β-Boswellic Acid
所属类别
生物化工:中草药成分

物理化学性质

熔点271℃
沸点600.3±55.0 °C(Predicted)
密度1.13±0.1 g/cm3(Predicted)
储存条件−20°C
溶解度氯仿(微溶)、甲醇(微溶)
酸度系数(pKa)4.28±0.70(Predicted)
形态neat
颜色白色至灰白色
LogP7.418 (est)

安全数据

危险性符号(GHS)
GHS07
警示词警告
危险性描述H302-H315-H319-H335
危险类别码36/37/38
安全说明26
WGK Germany3
海关编码2918300000

应用领域

用途1
用于含量测定/鉴定/药理实验等

常见问题列表

概述
11- 羰基 -β- 乙酰乳香酸(Acetyl-11-keto-β-boswellic acid,AKBA) 能显著地抑制 5-脂氧合酶(5-LO)的形成,从而发挥强大的抗炎抗氧化作用,其次对肿瘤、溃疡和免疫调节等疾病表现出良好的治疗前景。AKBA 可以通过抑制 TNF-α 诱导的 NF-κB 活化,从而抑制基质金属蛋白酶的活化,起到血管保护作用;同类化合物甘草酸和积雪草酸被报道,基于其良好的抗氧化作用,可通过调节体内不同细胞因子表达,从而有效抑制和逆转血管重构。为西黄丸药制剂中重要活性成分。
 西黄丸药制剂
图:西黄丸药制剂
西黄丸中 11-羰基-β-乙酰乳香酸的鉴别及含量测定
方法: 采用薄层色谱法和高效液相色谱法建立西黄丸中乳香类成分 11-羰基-β-乙酰乳香酸的方法。运用高效液相色谱法对其进行含量测定,其中 11-羰基-β-乙酰乳香酸含量最低为
0.27% ,最高为1.05% 。建立薄层色谱法和高效液相色谱法可用于西黄丸中 11-羰基-β-乙酰乳香酸的定性定量检验,可作为西黄丸现行法定检验标准中乳香显微鉴别的有益补充。
药理应用
羰基-β-乙酰乳香酸(Acetyl-11-keto-β-BoswellicAcid,AKBA)作为乳香提取物的主要药效成分之一。一定质量浓度的AKBA用于HL-60细胞即可观察到细胞出现凋亡的形态学改变,DNA凝胶电泳出现了凋亡特征性的DNA小分子降解片段带,流式细胞仪检测早期凋亡率最高可达39.49%,总凋亡率可达99.9%,并呈时间和剂量依赖性。所以,AK-BA能诱导HL-60细胞凋亡,其作用呈剂量和时间依赖性。KBA作为乳香的单体成分,诱导白血病细胞凋亡作用强,其作用呈一定的剂量和时间依赖性,在急性髓系白血病治疗领域具有良好的临床应用前景。
参考文献
【1】王醇,夏磊,宋志前,等. 乳香中 5 种乳香酸成分含量分析[J].中
国中药杂志,2011,36( 10)1330-1332
【2】崔锐,周金云. 乳香化学和药理的研究进展 [J]. 中国药学杂志,2003, 38(6): 407-410
生物活性
AKBA (Acetyl-11-keto-β-boswellic acid) 是一种从乳香中提取出的活性化合物,是新颖的 Nrf2 的活化剂。
靶点

Human Endogenous Metabolite

体外研究

AKBA (Acetyl-11-keto-β-boswellic acid) significantly reduced infarct volumes and apoptotic cells, and also increased neurologic scores by elevating the Nrf2 and HO-1 expression in brain tissues in middle cerebral artery occlusion (MCAO) rats at 48 hours post reperfusion. In primary cultured neurons, AKBA increased the Nrf2 and HO-1 expression, which provided protection against OGD-induced oxidative insult. Additionally, AKBA treatment increased Nrf2 binding activity to antioxidant-response elements (ARE).
AKBA (Acetyl-11-keto-β-boswellic acid) significantly inhibited human colon adenocarcinoma growth, showing arrest of the cell cycle in G1-phase and induction of apoptosis.
AKBA (Acetyl-11-keto-β-boswellic acid) triggered significant lipolysis in 3T3-L1 adipocytes as shown by reduced neutral lipids in cytosol and increased free fatty acids in culture medium. Increased lipolysis by AKBA was accompanied by up-regulation of lipolytic enzymes, adipocyte triglyceride lipase (ATGL) and hormone sensitive lipase (HSL), and a decreased expression of lipid droplet stability regulator perilipin. In addition, AKBA (Acetyl-11-keto-β-boswellic acid) treatment reduced phenotypic markers of mature adipocyte aP2, adiponectin and glut-4 in mature adipocytes.

体内研究

AKBA (Acetyl-11-keto-β-boswellic acid) significantly prevented the formation of intestinal adenomatous polyps without toxicity to mice. AKBA's activity both in the prevention of small intestinal and colonic polyps was more potently than aspirin. Histopathologic examination revealed that AKBA's effect, that is the reduction of polyp size and degree of dysplasia, was more prominent in larger sized polyps, especially those originating in colon.
AKBA (Acetyl-11-keto-β-boswellic acid) administration in mice effectively delayed the growth of HT-29 xenografts without signs of toxicity. The activity of AKBA was more potent than that of aspirin.
AKBA (Acetyl-11-keto-β-boswellic acid) exhibited anti-cancer activity in vitro and in vivo. With oral application in mice, AKBA significantly inhibited SGC-7901 and MKN-45 xenografts without toxicity.

"67416-61-9" 相关产品信息
37440-01-0 32509-66-3 4547-24-4 77-52-1 128-13-2 273730-59-9 28282-25-9 89913-60-0 39262-14-1 20784-50-3 114902-16-8 506-33-2 112-86-7